Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT03578874 Completed - Clinical trials for Hepatocellular Carcinoma

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

Start date: June 20, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the resectability after treatment with SECOX (sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally advanced hepatocellular carcinoma

NCT ID: NCT03575806 Completed - Clinical trials for Hepatocellular Carcinoma

Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Start date: January 9, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection. Patients will be assigned either to the experimental arm to receive autologous Tcm immunotherapy and TACE or to the active comparator (TACE alone).

NCT ID: NCT03575598 Completed - Clinical trials for Squamous Cell Carcinoma of the Oral Cavity

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

SNOW
Start date: August 30, 2018
Phase: Early Phase 1
Study type: Interventional

This is a window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative drugs, Sitravatinib and Nivolumab.

NCT ID: NCT03574792 Completed - Clinical trials for Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Start date: May 3, 2018
Phase: N/A
Study type: Interventional

This trial studies how well gabapentin, methadone, and oxycodone with or without venlafaxine hydrochloride work in managing pain in participants with stage II-IV squamous cell head and neck cancer undergoing chemoradiation therapy. Gabapentin may reduce the need for these pain medications if given at the start of radiation therapy. Methadone and oxycodone may help relieve pain caused by cancer. Venlafaxine hydrochloride may prevent or improve pain caused by cancer. It is now yet known whether giving gabapentin, methadone, and oxycodone with venlafaxine hydrochloride will work better in managing pain in participants with squamous cell head and neck cancer undergoing chemoradiation therapy.

NCT ID: NCT03574753 Completed - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP S1400K: c-MET Positive

Start date: March 16, 2018
Phase: Phase 2
Study type: Interventional

S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.

NCT ID: NCT03572582 Completed - Clinical trials for Carcinoma, Hepatocellular

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

IMMUTACE
Start date: June 14, 2018
Phase: Phase 2
Study type: Interventional

The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage hepatocellular carcinoma (HCC) as first line therapy.

NCT ID: NCT03569345 Completed - Clinical trials for Carcinoma, Basal Cell

Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate

Start date: November 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A prospective clinical, uncontrolled, open-label, explorative phase 2a trial on patients with histologically-confirmed superficial and nodular basal cell carcinoma (BCC). The study assesses tolerability and tumor clearance after laser-assisted topical delivery of topical ingenol mebutate.

NCT ID: NCT03564405 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma

Start date: December 5, 2016
Phase: N/A
Study type: Interventional

Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

NCT ID: NCT03562897 Completed - Carcinoma Clinical Trials

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Start date: October 25, 2018
Phase: Phase 2
Study type: Interventional

Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.

NCT ID: NCT03558503 Completed - Bladder Cancer Clinical Trials

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

OPTIMA II
Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

This Phase 2b, single-arm, multicenter study evaluated the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).